Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration.
Boullart AC, Aarntzen EH, Verdijk P, Jacobs JF, Schuurhuis DH, Benitez-Ribas D, Schreibelt G, van de Rakt MW, Scharenborg NM, de Boer A, Kramer M, Figdor CG, Punt CJ, Adema GJ, de Vries IJ. Boullart AC, et al. Cancer Immunol Immunother. 2008 Nov;57(11):1589-97. doi: 10.1007/s00262-008-0489-2. Epub 2008 Mar 6. Cancer Immunol Immunother. 2008. PMID: 18322684 Free PMC article.
Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.
Lesterhuis WJ, Schreibelt G, Scharenborg NM, Brouwer HM, Gerritsen MJ, Croockewit S, Coulie PG, Torensma R, Adema GJ, Figdor CG, de Vries IJ, Punt CJ. Lesterhuis WJ, et al. Cancer Immunol Immunother. 2011 Feb;60(2):249-60. doi: 10.1007/s00262-010-0942-x. Epub 2010 Nov 11. Cancer Immunol Immunother. 2011. PMID: 21069321 Free PMC article. Clinical Trial.
Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters.
Aarntzen EH, de Vries IJ, Göertz JH, Beldhuis-Valkis M, Brouwers HM, van de Rakt MW, van der Molen RG, Punt CJ, Adema GJ, Tacken PJ, Joosten I, Jacobs JF. Aarntzen EH, et al. Cancer Immunol Immunother. 2012 Nov;61(11):2003-11. doi: 10.1007/s00262-012-1263-z. Epub 2012 Apr 21. Cancer Immunol Immunother. 2012. PMID: 22527252 Free PMC article.
216 results